These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

429 related items for PubMed ID: 11504769

  • 1. Effects of orally active taxanes on P-glycoprotein modulation and colon and breast carcinoma drug resistance.
    Vredenburg MR, Ojima I, Veith J, Pera P, Kee K, Cabral F, Sharma A, Kanter P, Greco WR, Bernacki RJ.
    J Natl Cancer Inst; 2001 Aug 15; 93(16):1234-45. PubMed ID: 11504769
    [Abstract] [Full Text] [Related]

  • 2. Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and tRA96023.
    Minderman H, Brooks TA, O'Loughlin KL, Ojima I, Bernacki RJ, Baer MR.
    Cancer Chemother Pharmacol; 2004 May 15; 53(5):363-9. PubMed ID: 15060738
    [Abstract] [Full Text] [Related]

  • 3. IDN 5390: an oral taxane candidate for protracted treatment schedules.
    Pratesi G, Laccabue D, Lanzi C, Cassinelli G, Supino R, Zucchetti M, Frapolli R, D'Incalci M, Bombardelli E, Morazzoni P, Riva A, Zunino F.
    Br J Cancer; 2003 Mar 24; 88(6):965-72. PubMed ID: 12644838
    [Abstract] [Full Text] [Related]

  • 4. Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein.
    Brooks TA, Minderman H, O'Loughlin KL, Pera P, Ojima I, Baer MR, Bernacki RJ.
    Mol Cancer Ther; 2003 Nov 24; 2(11):1195-205. PubMed ID: 14617793
    [Abstract] [Full Text] [Related]

  • 5. A novel taxane active against an orthotopically growing human glioma xenograft.
    Laccabue D, Tortoreto M, Veneroni S, Perego P, Scanziani E, Zucchetti M, Zaffaroni M, D'Incalci M, Bombardelli E, Zunino F, Pratesi G.
    Cancer; 2001 Dec 15; 92(12):3085-92. PubMed ID: 11753988
    [Abstract] [Full Text] [Related]

  • 6. Enhancement by recombinant human interferon alfa of the reversal of multidrug resistance by MRK-16 monoclonal antibody.
    Fogler WE, Pearson JW, Volker K, Ariyoshi K, Watabe H, Riggs CW, Wiltrout RH, Longo DL.
    J Natl Cancer Inst; 1995 Jan 18; 87(2):94-104. PubMed ID: 7707396
    [Abstract] [Full Text] [Related]

  • 7. Oral efficacy and bioavailability of a novel taxane.
    Polizzi D, Pratesi G, Monestiroli S, Tortoreto M, Zunino F, Bombardelli E, Riva A, Morazzoni P, Colombo T, D'Incalci M, Zucchetti M.
    Clin Cancer Res; 2000 May 18; 6(5):2070-4. PubMed ID: 10815934
    [Abstract] [Full Text] [Related]

  • 8. Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative.
    Taraboletti G, Micheletti G, Rieppi M, Poli M, Turatto M, Rossi C, Borsotti P, Roccabianca P, Scanziani E, Nicoletti MI, Bombardelli E, Morazzoni P, Riva A, Giavazzi R.
    Clin Cancer Res; 2002 Apr 18; 8(4):1182-8. PubMed ID: 11948131
    [Abstract] [Full Text] [Related]

  • 9. Cellular bases of the antitumor activity of the novel taxane IDN 5109 (BAY59-8862) on hormone-refractory prostate cancer.
    Cassinelli G, Lanzi C, Supino R, Pratesi G, Zuco V, Laccabue D, Cuccuru G, Bombardelli E, Zunino F.
    Clin Cancer Res; 2002 Aug 18; 8(8):2647-54. PubMed ID: 12171897
    [Abstract] [Full Text] [Related]

  • 10. Antitumour and antiangiogenic effects of IDN 5390, a novel C-seco taxane, in a paclitaxel-resistant human ovarian tumour xenograft.
    Petrangolini G, Cassinelli G, Pratesi G, Tortoreto M, Favini E, Supino R, Lanzi C, Belluco S, Zunino F.
    Br J Cancer; 2004 Apr 05; 90(7):1464-8. PubMed ID: 15054472
    [Abstract] [Full Text] [Related]

  • 11. Overcoming multidrug resistance in taxane chemotherapy.
    Geney R, Ungureanu lM, Li D, Ojima I.
    Clin Chem Lab Med; 2002 Sep 05; 40(9):918-25. PubMed ID: 12435109
    [Abstract] [Full Text] [Related]

  • 12. A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes.
    Cassinelli G, Supino R, Perego P, Polizzi D, Lanzi C, Pratesi G, Zunino F.
    Int J Cancer; 2001 Jun 01; 92(5):738-47. PubMed ID: 11340581
    [Abstract] [Full Text] [Related]

  • 13. P-glycoprotein modulates ceramide-mediated sensitivity of human breast cancer cells to tubulin-binding anticancer drugs.
    Shabbits JA, Mayer LD.
    Mol Cancer Ther; 2002 Jan 01; 1(3):205-13. PubMed ID: 12467215
    [Abstract] [Full Text] [Related]

  • 14. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin.
    Mechetner E, Kyshtoobayeva A, Zonis S, Kim H, Stroup R, Garcia R, Parker RJ, Fruehauf JP.
    Clin Cancer Res; 1998 Feb 01; 4(2):389-98. PubMed ID: 9516927
    [Abstract] [Full Text] [Related]

  • 15. Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells.
    Stein U, Walther W, Shoemaker RH.
    J Natl Cancer Inst; 1996 Oct 02; 88(19):1383-92. PubMed ID: 8827016
    [Abstract] [Full Text] [Related]

  • 16. Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP).
    Vanhoefer U, Cao S, Harstrick A, Seeber S, Rustum YM.
    Ann Oncol; 1997 Dec 02; 8(12):1221-8. PubMed ID: 9496387
    [Abstract] [Full Text] [Related]

  • 17. [New taxanes and epothilone derivatives in clinical trials].
    Lavelle F.
    Bull Cancer; 2002 Apr 02; 89(4):343-50. PubMed ID: 12016034
    [Abstract] [Full Text] [Related]

  • 18. Anti-tumour activity of a panel of taxanes toward a cellular model of human cervical cancer.
    Gallo D, Ferlini C, Distefano M, Cantelmo F, Gaggini C, Fattorossi A, Riva A, Bombardelli E, Proietti E, Mancuso S, Scambia G.
    Cancer Chemother Pharmacol; 2000 Apr 02; 45(2):127-32. PubMed ID: 10663627
    [Abstract] [Full Text] [Related]

  • 19. A pharmacodynamic study of the P-glycoprotein antagonist CBT-1® in combination with paclitaxel in solid tumors.
    Kelly RJ, Robey RW, Chen CC, Draper D, Luchenko V, Barnett D, Oldham RK, Caluag Z, Frye AR, Steinberg SM, Fojo T, Bates SE.
    Oncologist; 2012 Apr 02; 17(4):512. PubMed ID: 22416063
    [Abstract] [Full Text] [Related]

  • 20. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
    Goble S, Bear HD.
    Surg Clin North Am; 2003 Aug 02; 83(4):943-71. PubMed ID: 12875604
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.